These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20075712)

  • 21. Bi-weekly paclitaxel and capecitabine as a second- or third-line treatment for advanced breast cancer: a pilot study.
    Kellokumpu-Lehtinen PL; Tuunanen T; Kautio AL; Lehtinen I; Tanner M
    Anticancer Res; 2013 Nov; 33(11):4941-5. PubMed ID: 24222133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
    Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
    Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Schwartzberg LS; Wang G; Somer BG; Blakely LJ; Wheeler BM; Walker MS; Stepanski EJ; Houts AC
    Clin Breast Cancer; 2014 Feb; 14(1):13-9. PubMed ID: 24268206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G
    Anticancer Res; 2013 Jun; 33(6):2743-6. PubMed ID: 23749935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.
    Crown JP; Diéras V; Staroslawska E; Yardley DA; Bachelot T; Davidson N; Wildiers H; Fasching PA; Capitain O; Ramos M; Greil R; Cognetti F; Fountzilas G; Blasinska-Morawiec M; Liedtke C; Kreienberg R; Miller WH; Tassell V; Huang X; Paolini J; Kern KA; Romieu G
    J Clin Oncol; 2013 Aug; 31(23):2870-8. PubMed ID: 23857972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab.
    Dellapasqua S; Bagnardi V; Bertolini F; Sandri MT; Pastrello D; Cancello G; Montagna E; Balduzzi A; Mancuso P; Luini A; Goldhirsch A; Colleoni M
    Breast; 2012 Jun; 21(3):309-13. PubMed ID: 22341133
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
    Tubiana-Mathieu N; Bougnoux P; Becquart D; Chan A; Conte PF; Majois F; Espie M; Morand M; Vaissiere N; Villanova G
    Br J Cancer; 2009 Jul; 101(2):232-7. PubMed ID: 19584872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
    Yamamoto D; Iwase S; Tsubota Y; Ariyoshi K; Kawaguchi T; Miyaji T; Sueoka N; Yamamoto C; Teramoto S; Odagiri H; Kitamura K; Nagumo Y; Yamaguchi T
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1183-9. PubMed ID: 25862350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer.
    Shien T; Doihara H; Nishiyama K; Masuda H; Nogami T; Ikeda H; Taira N
    Acta Med Okayama; 2011 Aug; 65(4):231-7. PubMed ID: 21860529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Oral combination chemotherapy with capecitabine and cyclophosphamide in combination with endocrine therapy and anti-HER2 therapy for advanced and metastatic breast cancer].
    Okamura R; Kato T; Sata R
    Nihon Rinsho; 2012 Sep; 70 Suppl 7():592-6. PubMed ID: 23350469
    [No Abstract]   [Full Text] [Related]  

  • 31. Lapatinib plus capecitabine for brain metastases in patients with human epidermal growth factor receptor 2-positive advanced breast cancer: a review of the Anatolian Society of Medical Oncology (ASMO) experience.
    Cetin B; Benekli M; Oksuzoglu B; Koral L; Ulas A; Dane F; Turker I; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Isıkdogan A; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
    Onkologie; 2012; 35(12):740-5. PubMed ID: 23207619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer.
    Corey-Lisle PK; Peck R; Mukhopadhyay P; Orsini L; Safikhani S; Bell JA; Hortobagyi G; Roche H; Conte P; Revicki DA
    Cancer; 2012 Jan; 118(2):461-8. PubMed ID: 21598243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Kordes S; Klümpen HJ; Weterman MJ; Schellens JH; Richel DJ; Wilmink JW
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1135-41. PubMed ID: 25822310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430.
    Schott AF; Barlow WE; Albain KS; Chew HK; Wade JL; Lanier KS; Lew DL; Hayes DF; Gralow JR; Livingston RB; Hortobagyi GN
    Oncologist; 2012; 17(2):179-87. PubMed ID: 22267853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG.
    Smorenburg CH; de Groot SM; van Leeuwen-Stok AE; Hamaker ME; Wymenga AN; de Graaf H; de Jongh FE; Braun JJ; Los M; Maartense E; van Tinteren H; Nortier JWR; Seynaeve C
    Ann Oncol; 2014 Mar; 25(3):599-605. PubMed ID: 24504445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase II study comparing capecitabine alone with capecitabine and oral cyclophosphamide in patients with advanced breast cancer-cyclox II.
    Harvey VJ; Sharples KJ; Isaacs RJ; Jameson MB; Jeffery GM; McLaren BR; Pollard S; Riley GA; Simpson AB; Hinder VA; Scott JN; Dzhelali MV; Findlay MP
    Ann Oncol; 2013 Jul; 24(7):1828-1834. PubMed ID: 23463624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].
    Horiguchi J; Takata D; Rokutanda N; Nagaoka R; Tokiniwa H; Odawara H; Kikuchi M; Sato A; Takeyoshi I
    Gan To Kagaku Ryoho; 2013 Sep; 40(9):1175-80. PubMed ID: 24047774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer.
    Vrdoljak E; Boban M; Omrcen T; Hrepic D; Fridl-Vidas V; Boskovic L
    Neoplasma; 2011; 58(2):172-8. PubMed ID: 21275468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity.
    Battelli N; Bittoni A; Pagliacci A; Zepponi L; Scartozzi M; Mariotti C; Cascinu S
    Tumori; 2011; 97(4):449-53. PubMed ID: 21989432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.